Lower Plasma Levels of Selective VGF (Non-Acronymic) Peptides in Bipolar Disorder: Comparative Analysis Reveals Distinct Patterns across Mood Disorders and Healthy Controls

dc.contributor.authorCocco, Cristina
dc.contributor.authorNoli, Barbara
dc.contributor.authorManconi, Barbara
dc.contributor.authorContini, Cristina
dc.contributor.authorManca, Elias
dc.contributor.authorPisanu, Claudia
dc.contributor.authorMeloni, Anna
dc.contributor.authorManchia, Mirko
dc.contributor.authorParibello, Pasquale
dc.contributor.authorChillotti, Caterina
dc.contributor.authorArdau, Raffaella
dc.contributor.authorSeverino, Giovanni
dc.contributor.authorSquassina, Alessio
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.converis.publication-id458294325
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/458294325
dc.date.accessioned2025-08-27T12:58:52Z
dc.date.available2025-08-27T12:58:52Z
dc.description.abstract<p><strong>Introduction:</strong> <br></p><p>Discriminating bipolar disorder (BD) from major depressive disorder (MDD) remains a challenging clinical task. Identifying specific peripheral biosignatures that can differentiate between BD and MDD would significantly increase diagnostic accuracy. Dysregulated neuroplasticity is implicated in BD and MDD, and psychotropic medications restore specific disrupted processes by increasing neurotrophic signalling. The nerve growth factor inducible vgf gene (non-acronymic) encodes a precursor protein named proVGF, which undergoes proteolytic processing to produce several VGF peptides, some of which were suggested to be implicated in mood disorders and have antidepressant effects. Since the presence of VGF peptides in humans has been exclusively investigated in brain and cerebrospinal fluid, we aimed to identify which VGF peptides are present in the plasma and to investigate whether their levels could differentiate BD from MDD as well as responders from non-responders to pharmacological interventions. <br></p><p><strong>Methods: </strong><br></p><p>VGF peptides were investigated in plasma from patients diagnosed with MDD (n = 37) or BD (n = 40 under lithium plus n = 29 never exposed to lithium), as well as healthy controls (HC; n = 36). <br></p><p><strong>Results: </strong><br></p><p>Three VGF peptides (TLQP-11, AQEE-14, and NAPP-19) were identified using spectrometry analysis of plasma from HC. These peptides were then measured in the entire sample using ELISA, which showed significantly lower levels of AQEE and NAPP in BD than in HC and MDD (p = 5.0 × 10<sup>−5</sup>, p = 0.001, respectively). <br></p><p><strong>Conclusion: </strong><br></p><p>Our findings suggest that lower plasma levels of NAPP and AQEE are specifically associated with BD, thus possibly representing a diagnostic biomarker in mood disorders.<br></p>
dc.format.pagerange160
dc.format.pagerange169
dc.identifier.eissn1423-0224
dc.identifier.jour-issn0302-282X
dc.identifier.olddbid199958
dc.identifier.oldhandle10024/182985
dc.identifier.urihttps://www.utupub.fi/handle/11111/45183
dc.identifier.urlhttps://doi.org/10.1159/000540673
dc.identifier.urnURN:NBN:fi-fe2025082788924
dc.language.isoen
dc.okm.affiliatedauthorManca, Elias
dc.okm.discipline3124 Neurology and psychiatryen_GB
dc.okm.discipline3124 Neurologia ja psykiatriafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherKarger Publishers
dc.publisher.countrySwitzerlanden_GB
dc.publisher.countrySveitsifi_FI
dc.publisher.country-codeCH
dc.relation.doi10.1159/000540673
dc.relation.ispartofjournalNeuropsychobiology
dc.relation.issue3-4
dc.relation.volume83
dc.source.identifierhttps://www.utupub.fi/handle/10024/182985
dc.titleLower Plasma Levels of Selective VGF (Non-Acronymic) Peptides in Bipolar Disorder: Comparative Analysis Reveals Distinct Patterns across Mood Disorders and Healthy Controls
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
000540673.pdf
Size:
417.23 KB
Format:
Adobe Portable Document Format